美國胸腔醫學會及感染症醫學會之社區型肺炎診斷及治療準則介紹

10.6666/ClinMed.202108_88(2).0081

曾馨儀；陳怡仁；林邑璁

社區型肺炎（community acquired pneumonia） ； 抗生素治療（antimicrobial therapy）

臨床醫學月刊

88卷2期（2021 / 08 / 27）

490 - 499

繁體中文

美國胸腔醫學會（American Thoracic Society, ATS）／美國感染症醫學會（Infectious Diseases Society of America, IDSA）針對社區型肺炎，上一版的指引在2007年發表，2019年底發表新的診斷及治療指引，將先前指引的敘述方式，改成Grading of Recommendations Assessment, Development, and Evaluation（GRADE）架構。此準則提出一系列的問題，並依照現有證據給予建議。此指引的範圍含診斷到抗生素治療，但不涵蓋臨床診斷標準，或是肺炎的預防。肺炎為一異質性極高的疾病，此指引提出的問題，並不包含照護病人的所有相關問題，而是一些經專家小組考量，較優先的核心問題。此外，雖然每個問題皆採用現有的高品質的研究，做系統性的回顧，但證據力仍時常不足。因此，臨床醫師的判斷和治療經驗，以及未來持續的研究仍然是相當重要的。

1. American Thoracic Society,Infectious Diseases Society of America(2005).Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.Am J Respir Crit Care Med,171,388-416.
2. El-Solh, AA,Pietrantoni, C,Bhat, A(2003).Microbiology of severe aspiration pneumonia in institutionalized elderly.Am J Respir Crit Care Med,167,1650-1654.
3. Garin, N,Genné, D,Carballo, S(2014).β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.JAMA Intern Med,174,1894-1901.
4. Horita, N,Otsuka, T,Haranaga, S(2016).Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis.Respirology,21,1193-1200.
5. Lee, JS,Giesler, DL,Gellad, WF(2016).Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review.JAMA,315,593-602.
6. Mandell, LA,Wunderink, RG,Anzueto, A(2007).Infectious Diseases Society of America / American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.Clin Infect Dis,44,S27-S72.
7. Metlay, JP,Waterer, GW,Long, AC(2019).Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.Am J Respir Crit Care Med,200,e45-e67.
8. Mortensen, EM,Copeland, LA,Pugh, MJ(2010).Diagnosis of pulmonary malignancy after hospitalization for pneumonia.Am J Med,123,66-71.
9. Nie, W,Li, B,Xiu, Q(2014).β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis.J Antimicrob Chemother,69,1441-1446.
10. Raz-Pasteur, A,Shasha, D,Paul, M(2015).Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: systematic review and meta-analysis.Int J Antimicrob Agents,46,242-248.
11. Sligl, WI,Asadi, L,Eurich, DT(2014).Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis.Crit Care Med,42,420-432.
12. Vardakas, KZ,Trigkidis, KK,Falagas, ME(2017).Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis.Clin Microbiol Infect,23,234-241.

1. 廖芳儀,黃建榮,林恭儀,周艷秋,Alexander T. H. Wu(2022)。大青龍湯與清冠一號遠距COVID-19治療與預防個案報告。中醫藥研究論叢，25(特刊)，13-20。